Trials / Terminated
TerminatedNCT06289894
A Study of BRY805 in Participants With Advanced Solid Tumors
A Phase I, Open-label, Single Arm Study to Evaluate the Safety, Tolerability, and Antitumor Activity of BRY805 in Participants With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- BioRay Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1 open label multicenter study to evaluate safety, tolerance and the maximum tolerance of BRY805 administered intravenously (IV) once every three weeks in participants with advanced solid tumors, so as to confirm the recommended phase 2 dose of BRY805 and obtain the preliminary efficacy information of participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BRY805 injection | BRY805 will be administered via IV infusion every 3 weeks. , Six dose levels of 0.3, 1, 3, 9,18 and 30 mg/kg will be tested |
Timeline
- Start date
- 2024-03-13
- Primary completion
- 2025-05-16
- Completion
- 2025-07-04
- First posted
- 2024-03-04
- Last updated
- 2025-11-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06289894. Inclusion in this directory is not an endorsement.